clinical trial · NCT04062981
Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome
SK Life Science, Inc.·phase1·completed·n = 15
Lennox Gastaut SyndromeCarisbamate
brief summary
Open-label extension study from YKP509C001 to evaluate the safety and tolerability of carisbamate in subjects with Lennox-Gastaut Syndrome (LGS).
started
May 3, 2019
primary completion
Dec 14, 2022
completion
Dec 14, 2022
last updated
Apr 4, 2024
detailed description
Subjects who successfully completed the YKP509C001 study and could benefit from continued exposure to carisbamate.
This is an open-label (OL), multi-center study of carisbamate in subjects with LGS, with safety assessments from Baseline (Visit 1) through the early termination (ET)/end of study (EOS) visit.
official title
Phase 1, Open-Label Study of Carisbamate in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol